Choose your preferred way to stay informed of new case launches and settlement deadlines
The filed complaint alleges that Pliant Therapeutics, Inc. made materially false and/or misleading statements and/or failed to disclose that: On February 7, 2025, Pliant announced that following a prespecified data review and recommendations by the trial’s independent Data Safety Monitoring Board, it had voluntarily paused enrollment and dosing in the ongoing BEACON-IPF Phase 2b trial of bexotegrast in patients with idiopathic pulmonary fibrosis. Following this news, PLRX’s stock price plummeted over 60% to open at $3.02 per share on February 10, 2025.
In order to be eligible to join the PLRX class action lawsuit, you must have incurred a loss on shares of Pliant Therapeutics, Inc. purchased during the class period listed above.
TOP
